AbbVie presented the detailed Phase 1 data for ABBV-295, its long-acting amylin analog, at the EASD 2026 meeting in Milan on September 30. The study reported up to 9.8% mean weight loss at 12 weeks. The more notable result was the dosing interval: a mean half-life of 10.7 to 12.3 days, and a once-monthly cohort that still reported 7.9% weight loss at week 13.
Every amylin drug in late development today is dosed weekly. That includes cagrilintide, petrelintide and eloralintide. ABBV-295 is the first to put monthly-dosing data on a conference slide, and it comes from a company with no obesity drug on the market. AbbVie paid $350 million for the asset in 2025, and this is its first full dataset.
Research-context information only. Compounds discussed below are research peptides, investigational drugs, or approved pharmaceuticals depending on the molecule; several are not approved by the FDA. Protocols, doses, and outcomes reported come from published research and company disclosures. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
ABBV-295 has never been available outside AbbVie's clinical program, and no vendor lists it.
What AbbVie Presented at EASD
The numbers come from the multiple-ascending-dose portion (Parts 2B/2C) of a Phase 1 trial, NCT06144684, per AbbVie's September 30 release:
- Design: randomized, double-blind within cohorts, placebo-controlled, single-center
- Participants: 60 total (45 on ABBV-295, 15 on placebo); mean age 41.5, mean BMI 29.3, 88% male
- Regimens: escalated to 4, 6 or 14 mg once weekly, 14 mg every other week, or 8 mg once monthly, for 12 to 13 weeks
| Regimen | Timepoint | Reported mean weight change |
|---|---|---|
| Once weekly (4 / 6 / 14 mg cohorts) | Week 12 | -7.8% to -9.8% |
| Every other week (14 mg) | Week 13 | -9.7% |
| Once monthly (8 mg) | Week 13 | -7.9% |
| Placebo | Week 12-13 | about -0.3% |
Pharmacokinetics. AbbVie reported a mean half-life of 10.7 to 12.3 days, a median time to peak concentration of 24 to 48 hours, and exposure that increased in proportion to dose. For comparison, a weekly-dosed peptide typically has a half-life of about a week. ABBV-295's half-life is closer to two weeks, which is what makes the every-other-week and monthly arms plausible.
Tolerability. Nausea was reported in 33.3% of ABBV-295 participants versus 20.0% on placebo, and diarrhea in 20.0% versus 0%. AbbVie reported 92% of gastrointestinal events as mild, no severe GI events, and a 4.4% discontinuation rate versus 0% on placebo. The March topline release said GI effects clustered in the first six weeks, which fits the escalation period.
"These detailed results showed meaningful weight loss alongside a half-life that could support dosing less frequently than once weekly," AbbVie's Dr. Primal Kaur said in the release. AbbVie moved ABBV-295 into Phase 2 in August 2026.
How to Read a 12-Week, 60-Person Result
Three caveats limit how far these numbers can be pushed:
- It is 12 weeks. Amylin and GLP-1 weight loss curves are usually still falling at week 12. The number is an early slope, not an endpoint. Fierce Biotech reported William Blair's view that roughly 10% at week 12 is "competitive across the amylin class." That is a statement about trajectory, not about where the drug ends up.
- The cohort was 88% male with a mean BMI of 29.3. Obesity trials typically enroll majority-female populations with mean BMIs in the mid-to-high 30s. The same analysts suggested that more women in later trials could produce larger reported losses. Either way, the population is not comparable to other trials.
- Monthly is one cohort. The 7.9% monthly figure comes from a single small arm. Phase 2 is where AbbVie has to show that monthly dosing holds up against weekly dosing in a larger, more typical population.
What the data does establish is that the molecule works through the amylin receptor at a clinically meaningful level, and that its pharmacokinetics are unusual for the class.
What It Means for Buyers
Nothing in the research-compound market changes this week, for three reasons.
ABBV-295 cannot be sourced. It is a proprietary AbbVie molecule, and outside the trial it exists only in AbbVie's manufacturing chain. Listings claiming to sell it would be mislabeled.
Cagrilintide is the amylin analog research vendors actually list. Cagrilintide is Novo Nordisk's long-acting amylin analog and the amylin half of the semaglutide/cagrilintide combination. In the REDEFINE 1 Phase 3 trial, published in the New England Journal of Medicine, the combination reported 20.4% mean weight loss at 68 weeks versus 3.0% on placebo. Cagrilintide is also once-weekly, which puts the ABBV-295 half-life in context. The cagrilintide buying guide covers vendor COA practice and per-milligram pricing, and the cagrilintide price comparison lists live offers.
Amylin is now a pharma-validated mechanism. AbbVie, Roche, Lilly and Novo all have amylin programs in clinical development. Community sources describe pairing cagrilintide with GLP-1-class compounds, most often in the retatrutide/cagrilintide stack.
Vendor listings for cagrilintide and other research compounds are sold labeled for research use only. Current discount codes are collected on the peptide deals page.
